AUNP 12

Pricing Availability   Qty
Description: Peptide inhibitor of the PD-1 signaling pathway
Purity: ≥95% (HPLC)
Datasheet
Citations
Reviews
Literature (1)

Biological Activity for AUNP 12

AUNP 12 is an immune checkpoint modulator targeting the programmed cell death 1 (PD-1) signaling pathway. It inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2. In the mouse splenocyte assay system, AUNP 12 rescues proliferation (EC50 values are 17 and 16 nM for PD-L1 and PD-L2, respectively) and enhances T-cell activity by restoring IFNγ release inhibited by PD-L1 and PD-L2 (EC50 values are 49 nM and 51 nM respectively). In a mouse Renca renal cell carcinoma model, AUNP 12 shows an additive antitumor effect when combined with Cyclophosphamide (Cat. No. 4091).

Technical Data for AUNP 12

M. Wt 3261.56
Formula C142H226N40O48
Sequence SNTSESFKFRVTQLAPKAQIKE SNTSESF*

(Modifications: Amide bridge= 8-7*, Glu-22 = C-terminal amide)

Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 1353563-85-5
PubChem ID 154701623
InChI Key ZBJUUYIGBAQYBN-QKLNNLIKSA-N
Smiles OC(CC[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H]([C@H](CC)C)NC([C@@H](NC([C@@H](NC([C@H](CCCCN)NC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@@H](NC([C@@]([H])(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@H](CO)NC([C@H](CCC(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CO)N)=O)CC(N)=O)=O)[C@@H](C)O)=O)CO)=O)=O)=O)=O)CCCCNC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](CC(N)=O)NC([C@H](CO)N)=O)=O)=O)=O)CCC(O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=CC=C4)=O)CCCNC(N)=N)=O)C(C)C)=O)[C@@H](C)O)=O)CCC(N)=O)=O)CC(C)C)=O)C)=O)=O)=O)C)=O)CCC(N)=O)=O)=O)=O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for AUNP 12

Solubility Soluble to 2 mg/ml in water

References for AUNP 12

References are publications that support the biological activity of the product.

Omstead et al (2022) CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model. Carcinogenesis 43 842 PMID: 35552655

Sasikumar et al (2019) A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy. Mol.Cancer Ther. 18 1081 PMID: 31015307

Zhan et al (2016) From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discov.Today 21 1027 PMID: 27094104


If you know of a relevant reference for AUNP 12, please let us know.

View Related Products by Product Action

View all Immune Checkpoint Inhibitors

Keywords: AUNP 12, AUNP 12 supplier, AUNP12, immune, checkpoint, programmed, cell, death, 1, PD-1, PD-L1, PD-L2, IFN, gamma, Interferon, Other, Apoptosis, Immune, Checkpoints, 7831, Tocris Bioscience

Citations for AUNP 12

Citations are publications that use Tocris products.

Currently there are no citations for AUNP 12. Do you know of a great paper that uses AUNP 12 from Tocris? Please let us know.

Reviews for AUNP 12

There are currently no reviews for this product. Be the first to review AUNP 12 and earn rewards!

Have you used AUNP 12?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.